Sezen Karakus, MD
Ophthalmology · Baltimore, MDNPI 1942669973
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,300 of the $10,357 with a category attached, or 70.5%. Dompe US, Inc. accounts for 94.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $9,006 and has fallen 92.2% since, to $703 in 2025.
Across 27 payments — averaging $383.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$10K
- Alcon$250
- Mallinckrodt Hospital Products Inc.$144
- Carl Zeiss Meditec, Inc.$60
- Sight Sciences, Inc.$22
- Kala Pharmaceuticals, Inc.$20
- plus $79 from 5 others
Across 12 payments — averaging $12,664 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$129K
- Dompe US, Inc.$23K
What the payments were for
- Consulting fees$7,30070%
- Speaking & faculty fees$2,09020%
- Food & beverage$9669%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 17 | $9,782 |
| Alcon | 1 | $250 |
| Mallinckrodt Hospital Products Inc. | 1 | $144 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
| Sight Sciences, Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Tearlab Corp | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$144
How this compares
$10,357 in reported general payments places this provider in the 85th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $91,115 |
| XiidraLifitegrast | 32 | $47,932 |
| MieboPerfluorohexyloctane/Pf | 17 | $22,092 |
| CequaCyclosporine | 21 | $21,376 |
| Cyclosporine | 39 | $19,518 |
| TyrvayaVarenicline Tartrate | 20 | $18,130 |
| Prednisolone Acetate | 106 | $5,314 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $3,351 |
| Loteprednol Etabonate | 13 | $1,428 |
| ErythromycinErythromycin Base | 117 | $1,148 |
| Ketorolac Tromethamine | 73 | $1,085 |
| Doxycycline Monohydrate | 30 | $700 |
| Ofloxacin | 67 | $650 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $307 |
| Brimonidine Tartrate | 12 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $18 | $91,11557 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $17 | $21,37621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Baltimore
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Neil BresslerBaltimore$265K
- Adrienne ScottBaltimore$170K
- Jennifer ThorneBaltimore$128K
- Earl CravenBaltimore$120K
- Peter CampochiaroBaltimore$103K
- Gail SchwartzBaltimore$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.